1. Search Result
Search Result
Results for "

toxins A

" in MedChemExpress (MCE) Product Catalog:

391

Inhibitors & Agonists

3

Screening Libraries

4

Fluorescent Dyes

9

Biochemical Assay Reagents

109

Peptides

16

Inhibitory Antibodies

68

Natural
Products

20

Isotope-Labeled Compounds

2

Click Chemistry

1

Oligonucleotides

Cat. No. Product Name Target Research Area Image
  • HY-P99583

    MEDI4893

    Bacterial Infection Inflammation/Immunology
    Suvratoxumab (MEDI4893) is a long-acting, high-affinity human anti-α-toxin monoclonal antibody (IgG1κ type). Suvratoxumab potently neutralizes α-toxin, a key S. aureus virulence factor. Suvratoxumab improves survival and reduces lung injury in an immunocompromised mice model of pneumonia. Suvratoxumab also enhances the antibacterial activity of Vancomycin (HY-B0671) or Linezolid (HY-10394) .
    Suvratoxumab
  • HY-P9929
    Bezlotoxumab
    1 Publications Verification

    BLA761046; MBL-CDB1; MDX-1388

    Bacterial Infection
    Bezlotoxumab (BLA761046; MBL-CDB1; MDX-1388) is a fully humanized IgG1/kappa monoclonal antibody directed against Clostridium difficile toxin B. Bezlotoxumab mediates the early reconstitution of gut microbiota to reduce the risk of recurrent Clostridium difficile infection (CDI). Bezlotoxumab can be used for the study of recurrent Clostridium difficile infection prevention .
    Bezlotoxumab
  • HY-P99277

    Anti-C. difficile Toxin A Recombinant Antibody

    Inhibitory Antibodies Infection
    Actoxumab (Anti-C. difficile Toxin A Recombinant Antibody) is a antitoxin antibody against C. difficile toxin A by neutralizing TcdA. Actoxumab prevents both the damage to the gut wall and the inflammatory response, which are associated with C. difficile. Actoxumab has synergy effect with Bezlotoxumab (HY-P9929) targeting TcdB .
    Actoxumab
  • HY-P9957

    ABthrax

    Bacterial Infection
    Raxibacumab (ABthrax) is a human IgG1 monoclonal antibody against Bacillus anthracis protective antigen (PA). Raxibacumab blocks the toxin’s deleterious effects by preventing binding of the protective antigen component of the anthrax toxin to its receptors in host cells, thereby blocking the toxin’s deleterious effects. Raxibacumab can be used for anti-anthrax research .
    Raxibacumab
  • HY-P9932

    ETI 204

    Bacterial Infection Cardiovascular Disease
    Obiltoxaximab (ETI 204) is the second and potent anti-protective antigen (PA) monoclonal antibody with immunogenicity. Obiltoxaximab plays a central role in anthrax toxin assembly and target cell intoxication, promoting survival, and inhibiting bacterial spread to the periphery in animal models. Obiltoxaximab can be used in the research of inhalational anthrax, bacteremia and toxemia .
    Obiltoxaximab
  • HY-P99551

    KBSA301; AR-301

    Antibiotic Bacterial Infection
    Tosatoxumab (AR-301; KBSA301) is a human immunoglobulin G1 monoclonal antibody that specifically neutralizes alpha-toxin (alpha-hemolysin; Hla) of S. aureus. Tosatoxumab binds to an N-terminal epitope of alpha-toxin, thereby preventing functional toxin pore oligomerisation. Tosatoxumab has the potential for passive immunotherapy in the S. aureus pneumonia as an adjunctive therapy to standard antibiotic agent. Recommend Isotope Control: Human IgG1 lambda1, Isotype Control (HY-P99992) .
    Tosatoxumab
  • HY-111965

    anti-EFNA4-ADC

    Antibody-Drug Conjugates (ADCs) DNA Alkylator/Crosslinker Antibiotic Apoptosis Cancer
    PF-06647263 is an ADC targeting EFNA4, consisting of EFNA4 Antibody (HY-P991109), ADC toxin Calicheamicin (HY-19609) and a linker. PF-06647263 exhibits anti-tumor activity and induces significant tumor regression in TNBC xenografts .
    PF-06647263
  • HY-P99532

    HuVTm1.1; TMA-15

    Inhibitory Antibodies Infection
    Urtoxazumab (TMA-15) is a humanizedized monoclonal antibody against Shiga toxin (Stx) 2 .
    Urtoxazumab
  • HY-P991167

    Bacterial Infection
    Vecantoxatug is a humanized monoclonal antibody targeting Clostridium tetani toxin (TeNT, neurotoxin). Vecantoxatug specifically binds to Clostridium tetani toxin, preventing the toxin from binding to cell receptors and thus exerting antitoxin activity. Vecantoxatug is promising for research of tetanus .
    Vecantoxatug
  • HY-P99800

    Inhibitory Antibodies Infection
    Pritoxaximab is an IgG1κ antibody targeting shiga toxin type 1 .
    Pritoxaximab
  • HY-P99447

    ASN-1

    Bacterial Infection
    Atidortoxumab is a human IgG1κ monoclonal antibody that targets Staph aureus alpha toxin .
    Atidortoxumab
  • HY-P99898

    Bacterial Others
    Setoxaximab is an IgG1-κ humanized chimeric antibody targeting shiga toxin type 1 .
    Setoxaximab
  • HY-P990943

    TNM-002

    Inhibitory Antibodies Inflammation/Immunology
    HY-P990943 is an tetanus toxin-targeting IgG1κ type human antibody, the recommed isotype control is Human IgG1 kappa, Isotype Control (HY-P99001) .
    Siltartoxatug
  • HY-P992417

    CD20 Apoptosis Cancer
    MT-3724 is a CD20-targeted endotoxin B. MT-3724 binds to CD20, triggers receptor internalization, traffics to the endoplasmic reticulum, and induces permanent ribosomal inactivation to mediate cell killing. MT-3724 can inhibit protein synthesis and promote tumor cell apoptosis. MT-3724 can be used for the research of relapsed or refractory B-cell non-Hodgkin’s lymphomas and diffuse large B-cell lymphoma .
    MT-3724
  • HY-P992123

    AZD-5148

    Bacterial Infection
    Ombetoxabart is a humanized IgG1-κ monoclonal antibody targeting TcdB (Clostridioides difficile toxin B), which exerts its function by neutralizing the toxicity of TcdB. Ombetoxabart can be used for the study of Clostridioides difficile infection .
    Ombetoxabart
  • HY-P992488

    ZV0501 Antibody

    Transmembrane Glycoprotein ADC Antibody Cancer
    ZV05 (ZV0501 Antibody) is an anti-5T4 monoclonal antibody with an EC50 of 4.3 ng/mL against h5T4. ZV05 does not induce apoptosis or interfere with cell cycle progression. ZV05 accumulates specifically in 5T4-positive tumor xenografts. ZV05 can serve as the antibody component of antibody-active molecule conjugates (ADCs) to bind the 5T4 glycoprotein, thereby enabling targeted delivery of toxins. ZV05 is used in studies of 5T4-positive cancers, including triple-negative breast cancer .
    ZV05

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

 

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

 

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: